High frequency of linezolid-associated thrombocytopenia and anemia among patients with end-stage renal disease

Clinical Infectious Diseases

Volumn 42, Issue 1, 2006, Pages 66-72

  Wu, Vin Cent ^a   Wang, Yu Ting ^a   Wang, Cheng Yi ^a   Tsai, I Jung ^a   Wu, Kwan Dun ^a   Hwang, Joey Jen ^a   Hsueh, Po Ran ^a  

^a NATIONAL TAIWAN UNIVERSITY HOSPITAL   (Taiwan)

Author keywords

[No Author keywords available]

Indexed keywords

LINEZOLID;

ADULT; AGED; ANEMIA; ARTICLE; BACTERIAL INFECTION; CATHETER INFECTION; CONTROLLED STUDY; DIABETES MELLITUS; DISEASE SEVERITY; DRUG EFFICACY; DRUG TOLERABILITY; FEMALE; HEMODIALYSIS; HUMAN; KIDNEY FAILURE; LIVER DYSFUNCTION; LOGISTIC REGRESSION ANALYSIS; MAJOR CLINICAL STUDY; MALE; MORBIDITY; PANCYTOPENIA; PRIORITY JOURNAL; RISK FACTOR; SURVIVAL; THROMBOCYTE COUNT; THROMBOCYTOPENIA;

ACETAMIDES; AGED; AGED, 80 AND OVER; ANEMIA; ANTI-INFECTIVE AGENTS; CASE-CONTROL STUDIES; FEMALE; GRAM-POSITIVE BACTERIAL INFECTIONS; HUMANS; KIDNEY FAILURE, CHRONIC; MALE; MIDDLE AGED; OXAZOLIDINONES; RENAL DIALYSIS; RETROSPECTIVE STUDIES; THROMBOCYTOPENIA;

EID: 29244444185     PISSN: 10584838     EISSN: None     Source Type: Journal    
DOI: 10.1086/498509     Document Type: Article

References (37)

1. Krishnasami Z, Carlton D, Bimbo L, et al. Management of hemodialysis catheter-related bacteremia with an adjunctive antibiotic lock solution. Kidney Int 2002; 61:1136-42.
2. D'Agata EM, Green WK, Schulman G, et al. Vancomycin-resistant enterococci among chronic hemodialysis patients: a prospective study of acquisition. Clin Infect Dis 2001; 32:23-9.
3. Stevens DL, Herr D, Lampiris H, et al. Linezolid versus vancomycin for the treatment of methicillin-resistant Staphylococcus aureus infections. Clin Infect Dis 2002; 34:1481-90.
4. Perry CM, Jarvis B. Linezolid: a review of its use in the management of serious gram-positive infections. Drugs 2001; 61:525-51.
5. Moellering RC. Linezolid: the first oxazolidinone antimicrobial. Ann Intern Med 2003; 138:135-42.
6. Bernstein WB, Trotta RF, Rector JT, et al. Mechanisms for linezolid-induced anemia and thrombocytopenia. Ann Pharmacother 2003; 37: 517-20.
7. Whitehouse T, Cepeda JA, Shulman R, et al. Pharmacokinetic studies of linezolid and teicoplanin in the critically ill. J Antimicrob Chemother 2005; 55:333-40.
8. Gee T, Ellis R, Marshall G, et al. Pharmacokinetics and tissue penetration of linezolid following multiple oral doses. Antimicrob Agents Chemother 2001; 45:1843-6.
9. Howden BP, Ward PB, Charles PG, et al. Treatment outcomes for serious infections caused by methicillin-resistant Staphylococcus aureus with reduced vancomycin susceptibility. Clin Infect Dis 2004; 38:521-8.
10. Brier ME, Stalker DJ, Aronoff GR, et al. Pharmacokinetics of linezolid in subjects with renal dysfunction. Antimicrob Agents Chemother 2003; 47:2775-80.
11. Fiaccadori E, Maggiore U, Rotelli C, et al. Removal of linezolid by conventional intermittent hemodialysis, sustained low-efficiency dialysis, or continuous venovenous hemofiltration in patients with acute renal failure. Crit Care Med 2004; 32:2437-42.
12. Attassi K, Hershberger E, Alam R, Zervos MJ. Thrombocytopenia associated with linezolid therapy. Clin Infect Dis 2002; 34:695-8.
13. Senneville E, Legout L, Valette M, et al. Risk factors for anaemia in patients on prolonged linezolid therapy for chronic osteomyelitis: a case-control study. J Antimicrob Chemother 2004; 54:798-802.
14. Gerson SL, Kaplan SL, Bruss JB, et al. Hematologic effects of linezolid: summary of clinical experience. Antimicrob Agents Chemother 2002; 46:2723-6.
15. Bonomini M, Sirolli V. Uremic toxicity and anemia. J Nephrol 2003; 16:21-8.
16. Radtke HW, Claussner A, Erbes PM, et al. Serum erythropoietin concentration in chronic renal failure: relationship to degree of anemia and excretory renal function. Blood 1979; 54:877-84.
17. Rath CE, Mailliard JA, Schreiner GE. Bleeding tendency in uremia. N Engl J Med 1957; 257:808-11.
18. Stewart JH. Platelet numbers and life span in acute and chronic renal failure. Thromb Diath Haemorrh 1967; 17:532-42.
19. Bone RC. Immunologic dissonance: a continuing evolution in our understanding of the systemic inflammatory response syndrome (SIRS) and the multiple organ dysfunction syndrome (MODS). Ann Intern Med 1996; 125:680-7.
20. de Mendonca A, Vincent JL, Suter PM, et al. Acute renal failure in the ICU: risk factors and outcome evaluated by the SOFA score. Intensive Care Med 2000; 26:915-21.
21. Rubinstein E, Cammarata S, Oliphant T, Wunderink R. Linezolid (PNU-100766) versus vancomycin in the treatment of hospitalized patients with nosocomial pneumonia: a randomized, double-blind, multicenter study. Clin Infect Dis 2001; 32:402-12.
22. Lord H, Jean N, Dumont M, et al. Comparison between tinzaparin and standard heparin for chronic hemodialysis in a Canadian center. Am J Nephrol 2002; 22:58-66.
23. Astor BC, Muntner P, Levin A, et al. Association of kidney function with anemia: the Third National Health and Nutrition Examination Survey (1988-1994). Arch Intern Med 2002; 162:1401-8.
24. Kuter DJ, Tillotson GS. Hematologic effects of antimicrobials: focus on the oxazolidinone linezolid. Pharmacotherapy 2001; 21:1010-3.
25. Rao N, Ziran BH, Wagener MM, et al. Similar hematologic effects of long-term linezolid and vancomycin therapy in a prospective observational study of patients with orthopedic infections. Clin Infect Dis 2004; 38:1058-64.
26. Swaney SM, Aoki H, Ganoza MC, Shinabarger DL. The oxazolidinone linezolid inhibits initiation of protein synthesis in bacteria. Antimicrob Agents Chemother 1998; 42:3251-5.
27. Strauss R, Wehler M, Mehler K, et al. Thrombocytopenia in patients in the medical intensive care unit: bleeding prevalence, transfusion requirements, and outcome. Crit Care Med 2002; 30:1765-71.
28. French G. Safety and tolerability of linezolid. J Antimicrob Chemother 2003; 51(Suppl 2):ii, 45-53.
29. 51Cr-labeled platelets. In: Paulus JM, ed. Platelet kinetics. Amsterdam: North-Holland, 1971: 317-23.
30. Grau S, Morales-Molina JA, Mateu-de Antonio J, et al. Linezolid: low pre-treatment platelet values could increase the risk of thrombocytopenia. J Antimicrob Chemother 2005; 56:440-1.
31. Reilly RF. The pathophysiology of immune-mediated heparin-induced thrombocytopenia. Semin Dial 2003; 16:54-60.
32. Ozdemir O, Sayinalp NM, Haznedaroglu I, et al. Mean platelet volume, platelet count and platelet dimensional width during hemodialysis. Thromb Res 1997; 86:405-8.
33. Verbeelen D, Jochmans K, Herman AG, et al. Evaluation of platelets and hemostasis during hemodialysis with six different membranes. Nephron 1991; 59:567-72.
34. Craddock PR, Fehr J, Dalmasso AP, et al. Hemodialysis leukopenia: pulmonary vascular leukostasis resulting from complement activation by dialyzer cellophane membranes. J Clin Invest 1977; 59:879-88.
35. Fung HB, Kirschenbaum HL, Ojofeitimi BO. Linezolid: an oxazolidinone antimicrobial agent. Clin Ther 2001; 23:356-91.
36. 14C]linezolid to healthy human subjects. Drug Metab Dispos 2001; 29:1136-45.
37. Schroeder TH, Hansen M, Stephan M, et al. Elimination of linezolid by an in vitro extracorporeal circuit model. Int J Artif Organs 2004; 27:473-9.